Skip to main content
SpringerLink
Log in

Multiple Sclerosis: Experience with Large Clinical Trials

  • Chapter
Clinical Trials in Neurology

  • 263 Accesses

Abstract

Until recently, multiple sclerosis (MS) was considered largely an untreatable disorder. Therapy was limited to the alleviation of symptoms, and corticosteroid or ACTH treatment of acute relapses. The last decade has been a period of great advances, culminating in the licensure of three agents demonstrated to be of benefit in relapsing MS. Presently, there are more than 100 potential therapies for MS at varying stages of testing.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 169.00
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD 299.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info
Hardcover Book
USD 219.99
Price excludes VAT (USA)
  • Durable hardcover edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. Lublin FD, Reingold SC. Defining the clinical course of multiple sclerosis: results of an international survey. Neurology 1996; 46: 907–911.

    Article  PubMed  CAS  Google Scholar 

  2. Weinshenker BG, Bass B, Rice GPA, Noseworthy J, Carriere W, Baskerville J, et al. The natural history of multiple sclerosis: a geographically based study. 2. Predictive value of the early clinical course. Brain 1989; 112: 1419–1428.

    Article  PubMed  Google Scholar 

  3. Muller R. Studies in disseminated sclerosis. Acta Med Scand 1949; 133 (Suppl 222): 1–214.

    Google Scholar 

  4. Kurtzke JF, Beebe GW, Nagler B, Kurland LT, Auth TL. Studies on the natural history of multiple sclerosis. 8. Early prognostic features of the later course of the illness. J Chron Dis 1977; 30: 819–830.

    Article  PubMed  CAS  Google Scholar 

  5. Goodkin DE, Hertsgaard D, Rudick RA. Exacerbation rates and adherence to disease type in a prospectively followed-up population with multiple sclerosis: implications for clinical trials. Arch Neurol 1989; 46: 1107–1112.

    Article  PubMed  CAS  Google Scholar 

  6. Hauser SL, Dawson DM, Lehrich JR, Beal MF, Kevy SV, Propper RD, et al. Intensive immunosuppression in progressive multiple sclerosis: a randomized, three-arm study of high-dose intravenous cyclophosphamide, plasma exchange, and ACTH. N Engl J Med 1983; 308: 173–180.

    Article  PubMed  CAS  Google Scholar 

  7. Myers LW, Fahey JL, Moody DJ, Mickey MR, Frane MV, Ellison GW. Cyclophosphamide “pulses” in chronic progressive multiple sclerosis: a preliminary clinical trial. Arch Neurol 1987; 44: 828–832.

    Article  PubMed  CAS  Google Scholar 

  8. The Multiple Sclerosis Study Group. Efficacy and toxicity of cyclosporine in chronic progressive multiple sclerosis: a randomized, double-blind, placebo-controlled clinical trial. Ann Neurol 1990; 27: 591–605.

    Google Scholar 

  9. The Canadian Cooperative Multiple Sclerosis Group. The Canadian cooperative trial of cyclophosphamide and plasma exchange in progressive multiple sclerosis. Lancet 1991; 337: 441–446.

    Google Scholar 

  10. The IFNB Multiple Sclerosis Study Group. Interferon beta-lb is effective in relapsing-remitting multiple sclerosis. I. Clinical results of a multicenter, randomized, double-blind, placebo-controlled trial. Neurology 1993; 43: 655–661.

    Google Scholar 

  11. Johnson KP, Brooks BR, Cohen JA, Ford CC, Goldstein J, Lisak RP, et al. Copolymer 1 reduces the relapse rate and improves disability in relapsing-remitting multiple sclerosis: results of a phase III multicenter, double-blind, placebo-controlled trial. Neurology 1995; 45: 1268–1276.

    Article  PubMed  CAS  Google Scholar 

  12. Jacobs LD, Cookfair DL, Rudick RA, Herndon RM, Richert JR, Salazar AM, et al. Intramuscular interferon beta-la for disease progression in relapsing multiple sclerosis. Ann Neurol 1996; 39: 285–294.

    Article  PubMed  CAS  Google Scholar 

  13. Hulley SR, Cummings SR. Designing clinical research: an epidemiological approach. Baltimore: Williams and Wilkins, 1988.

    Google Scholar 

  14. Clagett N. The biological IND. In: Mathieu M, editor. Biologics development: a regulatory overview. Waltham, MA: Paraxel International, 1993: 53–75.

    Google Scholar 

  15. Meinert CL. Clinical trials: design, conduct and analysis. Oxford: Oxford University Press, 1986.

    Google Scholar 

  16. Rose AS, Namerow NS, Kuzma JW, Scheinberg LC, Brown AJ, Rumberg J, et al. Cooperative study in the evaluation of therapy in multiple sclerosis: ACTH vs placebo–final report. Neurology 1970; 20: 1–59.

    PubMed  CAS  Google Scholar 

  17. Willoughby EW, Paty DW. Scales for rating impairment in multiple sclerosis: a critique. Neurology 1988; 38: 1793–1798.

    Article  PubMed  CAS  Google Scholar 

  18. Kurtzke JE Rating neurologic impairment in multiple sclerasis: an expanded disability status scale (EDSS). Neurology 1983;33:1444–1452.

    Google Scholar 

  19. Ellison GW, Myers LW, Leake BD, Mickey MR, Ke D, Syndulko K, et al. Design strategies in multiple sclerosis clinical trials. Ann Neurol 1994; 36: S108 - S112.

    Article  PubMed  Google Scholar 

  20. Weinshenker BG, Issa M, Baskerville J. Long-term and shortterm outcome of multiple sclerosis: a 3-year follow-up study. Arch Neurol 1996; 53: 353–358.

    Article  PubMed  CAS  Google Scholar 

  21. Amato MP, Fratiglioni L, Groppi C, Siracusa G, Amaducci L. Interrater reliability in assessing functional systems and dis ability on the Kurtzke scale in multiple sclerosis. Arch Neurol 1988; 45: 746–748.

    Article  PubMed  CAS  Google Scholar 

  22. Noseworthy JH, Vandervoort MK, Wong CJ, Ebers GC, the Canadian Cooperative MS Study Group. Interrater variability with the expanded disability status scale (EDSS) and func tional systems (FS) in a multiple sclerosis clinical trial. Neu rology 1990; 40: 971–975.

    CAS  Google Scholar 

  23. Goodkin DE, Cookfair D, Wende K, Bourdette D, Scherokman B, et al. Inter-and intrarater scoring agreement Society Clinical Outcomes Assessment Task Force. Ann Neurol using grades 1.0 to 3.5 of the Kurtzke Expanded Disability Status Scale (EDSS). Neurology 1992; 42: 859–863.

    CAS  Google Scholar 

  24. Schwid SR, Goodman AD, Mattson DH,Mihai C, Donohue KM, Petrie MD, et al. The measurement of ambulatory impairment in multiple sclerosis. Neurology 1997; 49: 1419–1424.

    Article  PubMed  CAS  Google Scholar 

  25. Goodkin DE, Hertsgaard D, Seminary J. Upper extremity function in multiple sclerosis: improving assessment sensitivity with box-and-block and nine-hole peg tests. Arch Phys Med Rehabil 1988; 69: 850–854.

    PubMed  CAS  Google Scholar 

  26. Goodkin DE, Rudick RA, Medendorp SV, Daughtry MM, Schwetz KM, Fischer J, et al. Low-dose (7.5 mg) oral metho trexate reduces the rate of progression in chronic progressive multiple sclerosis. Ann Neurol 1995; 37: 30–41.

    Article  PubMed  CAS  Google Scholar 

  27. Syndulko K, Tourtellotte WW, Baumhefner RW, Ellison GW, Myers LW, Belendiuk G, et al. Neuroperformance evaluation of multiple sclerosis disease progression in a clinical trial: impli cations for neurological outcomes. J Neurol Rehabil 1993; 7: 153–176.

    Google Scholar 

  28. Heaton RK, Nelson LM, Thompson DS, Burks JS, Franklin GM. Neuropsychological findings in relapsing-remitting and chronic-progressive multiple sclerosis. J Consult Clin Psychol 1985; 53: 103–110.

    Article  PubMed  CAS  Google Scholar 

  29. Rao SM, Leo GJ, Bernardin L, Unverzagt F. Cognitive dysfunction in multiple sclerosis. I. Frequency, patterns, and prediction. Neurology 1991; 41: 685–691.

    Article  PubMed  CAS  Google Scholar 

  30. Rao SM, Leo GJ, Haughton VM, St. Aubin-Faubert P, Bernadin L. Correlation of magnetic resonance imaging with neuropsychological testing in multiple sclerosis. Neurology 1989; 39: 161–166.

    Article  PubMed  CAS  Google Scholar 

  31. Hohol MJ, Guttmann CRG, Orav J, Mackin GA, Kikinis R, Khoury SJ, et al. Serial neuropsychological assessment and magnetic resonance imaging analysis in multiple sclerosis. Arch Neurol 1997; 54: 1018–1025.

    Article  PubMed  CAS  Google Scholar 

  32. Fischer JS, Foley FW, Aikens JE, Ericson GD, Rao SM, Shindell S. What do we really know about cognitive dysfunction, affective disorders, and stress in multiple sclerosis? A practitioner’s guide. J Neurol Rehabil 1994; 8: 151–164.

    CAS  Google Scholar 

  33. Rao SM, Leo GJ, Ellington L, Nauertz T, Bernardin L, Unverzagt E Cognitive dysfunction in multiple sclerosis. II. Impact on employment and social functioning. Neurology 1991; 41: 692–696.

    Article  PubMed  CAS  Google Scholar 

  34. Durelli L, Bongioanni MR, Cavallo R, Ferrero B, Ferri R, Ferrio MF, et al. Chronic systemic high-dose recombinant interferon alfa-2a reduces exacerbation rate, MRI signs of disease activity, and lymphocyte interferon gamma production in relapsing-remitting multiple sclerosis. Neurology 1994; 44: 406–413.

    Article  PubMed  CAS  Google Scholar 

  35. Fischer JS. Use of neuropsychologic outcome measures in multiple sclerosis clinical trials: current status and strategies for improving multiple sclerosis clinical trial design. In: Goodkin DE, Rudick RA, editors. Multiple sclerosis: advances in clinical trial design, treatment and future perspectives. Berlin Heidelberg New York: Springer, 1996: 123–144.

    Google Scholar 

  36. Smits RCF, Emmen HH, Bertelsmann FW, Kulig BM, van Loenen AC, Polman CH. The effects of 4-aminopyridine on cognitive function in patients with multiple sclerosis: a pilot study. Neurology 1994; 44: 1701–1705.

    Article  PubMed  CAS  Google Scholar 

  37. Pliskin NH, Hamer DP, Goldstein DS, Towle VL, Reder AT, Noronha A, et al. Improved delayed visual reproduction test performance in multiple sclerosis patients receiving interferon 13-lb. Neurology 1996; 47: 1463–1486.

    Article  PubMed  CAS  Google Scholar 

  38. Fischer JS, Priore RL, Jacobs LD, Cookfair DL, Rudick RA, Herndon RM et al. Neuropsychological effects of Interferon Beta-la in relapsing multiple sclerosis. Ann Neurol 2000, in press.

    Google Scholar 

  39. Rudick R, Antel J, Confavreux C, Cutter G, Ellison G, Fischer J, Pullicino P, et al. Recommendations from the National Multiple Sclerosis 1997; 42: 379–382.

    CAS  Google Scholar 

  40. Cutter GR, Baier ML, Rudick RA, Cookfair DL, Fischer JS, Petkau J et al. Development of a multiple sclerosis functional composite as a clinical trial outcome measure. Brain 1999; 122: 871–872.

    Article  PubMed  Google Scholar 

  41. Kirby N. The clinical testing of biologics. In: Mathieu M, editor. Biologics development: a regulatory overview. Waltham, MA: Paraxel International, 1993: 53–75.

    Google Scholar 

  42. Evans AC, Frank JA, Antel J, Miller DH. The role of MRI in clinical trials of multiple sclerosis: comparison of image processing techniques. Ann Neurol 1997; 41: 125–132.

    Article  PubMed  CAS  Google Scholar 

  43. Paty DW, Li DKB, the UBC MS/MRI Study Group, the IFNB Multiple Sclerosis Study Group. Interferon beta-lb is effective in relapsing-remitting multiple sclerosis. II. MRI analysis results of a multicenter, randomized, double-blind, placebocontrolled trial. Neurology 1993; 43: 662–667.

    Article  PubMed  CAS  Google Scholar 

  44. Miller DH, Albert PS, Barkhof F, Francis G, Frank JA, Hodgkinson S, et al. Guidelines for the use of magnetic resonance techniques in monitoring the treatment of multiple sclerosis. Ann Neurol 1996; 39: 6–16.

    Article  PubMed  CAS  Google Scholar 

  45. Harris JO, Frank JA, Patronas N, McFarlin DE, McFarland HF. scans in patients with early, relapsing-remitting multiple sclerosis: implications for clinical trials and natural history. Ann Neurol 1991; 29: 548–555.

    Article  PubMed  CAS  Google Scholar 

  46. Thompson AJ, Miller D, Youl B, MacManus D, Moore S, Kingsley D, et al. Serial gadolinium-enhanced MRI in relapsing-remitting multiple sclerosis of varying disease duration. Neurology 1992; 42: 60–63.

    Article  PubMed  CAS  Google Scholar 

  47. Simon JH, Jacobs LD, Campion M, Wende K, Simonian N, Cookfair DL, et al. Magnetic resonance studies of intramuscular interferon 13-la for relapsing multiple sclerosis. Ann Neurol 1998; 43: 79–87.

    Article  PubMed  CAS  Google Scholar 

  48. McFarland HF, Frank JA, Albert PS, Smith ME, Martin R, Harris JO, et al. Using gadolinium-enhanced magnetic resonance imaging lesions to monitor disease activity in multiple sclerosis. Ann Neurol 1992; 32: 758–766.

    Article  PubMed  CAS  Google Scholar 

  49. Nauta JJP, Thompson AJ, Barkhof F, Miller DH. Magnetic resonance imaging in monitoring the treatment of multiple sclerosis patients: statistical power of parallel-groups and crossover designs. J Neurol Sci 1994; 122: 6–14.

    Article  PubMed  CAS  Google Scholar 

  50. Goodkin DE, Rudick RA, VanderBrug Medendorp S, et al. Low-dose oral methotrexate in chronic progressive multiple sclerosis: analyses of serial MRIs. Neurology 1996; 47: 1153 1157.

    Google Scholar 

  51. The IFNB Multiple Sclerosis Study Group, University of British Columbia MS/MRI Analysis Group. Interferon beta-lb in the treatment of multiple sclerosis: final outcome of the randomized, controlled trial. Neurology 1995; 45: 1277–1285.

    Google Scholar 

  52. Stone LA, Albert PS, Smith ME, DeCArli C, Armstrong MR, McFarlin DE, et al. Changes in the amount of diseased white matter over time in patients with relapsing-remitting multiple sclerosis. Neurology 1995; 45: 1808–1814.

    Article  PubMed  CAS  Google Scholar 

  53. Truyen L, van Waesberghe JHTM, van Walderveen MAA, van Osten BW, Polman CH, Hommes OR, et al. Accumulation of hypointense lesions (“black holes”) on T1 spin-echo MRI correlates with disease progression in multiple sclerosis. Neurology 1996; 47: 1469–1476.

    Article  PubMed  CAS  Google Scholar 

  54. Gass A, Barker GJ, Kidd D, Thorpe JW, MacManus D, Brennan A, et al. Correlation of magnetization transfer ratio with clinical disability in multiple sclerosis. Ann Neurol 1994; 36: 62–67.

    Article  PubMed  CAS  Google Scholar 

  55. Cohen SR, Herndon RM, McKhann GM. Radioimmunoassay of myelin basic protein in spinal fluid: an index of active demyelination. N Engl J Med 1976; 295: 1455–1457.

    Article  PubMed  CAS  Google Scholar 

  56. Whitaker JN, Layton BA, Herman PK, Kachelhofer RD, Burgard S, Bartolucci AA. Correlation of myelin basic protein-like material in cerebrospinal fluid of multiple sclerosis patients with their response to glucocorticoid treatment. Ann Neurol 1993; 33: 10–17.

    Article  PubMed  CAS  Google Scholar 

  57. Whitaker JN. The presence of immunoreactive myelin basic protein peptide in urine of persons with multiple sclerosis. Ann Neurol 1987; 22: 648–655.

    Article  PubMed  CAS  Google Scholar 

  58. Whitaker JN, Kachelhofer RD, Bradley EL, Burgard S, Layton BA, Reder AT, et al. Urinary myelin basic protein-like material as a correlate of the progression of multiple sclerosis. Ann Neurol 1995; 38: 625–632.

    Article  PubMed  CAS  Google Scholar 

  59. Whitaker JN, Williams PH, Layton BA, McFarland HF, Stone LA, Smith ME, et al. Correlation of clinical features and findings on cranial magnetic resonance imaging with urinary myelin basic protein-like material in patients with multiple sclerosis. Ann Neurol 1994; 35: 577–585.

    Article  PubMed  CAS  Google Scholar 

  60. Kaji R, Happel L, Sumner AJ. Effects of digitalis on clinical symptoms and conduction variables in patients with multiple sclerosis. Ann Neurol 1990; 28: 582–584.

    Article  PubMed  CAS  Google Scholar 

  61. Davis FA, Stefoski D, Rush J. Orally administered 4aminopyridine improves clinical signs in multiple sclerosis. Ann Neurol 1990; 27: 186–192.

    Article  PubMed  CAS  Google Scholar 

  62. van Diemen HAM, Polman CH, van Dongen TMMM, van Loenen AC, Nauta JJP, Taphoorn MJB, et al. The effect of 4aminopyridine on clinical signs in multiple sclerosis: a randomized, placebo-controlled, double-blind, cross-over study. Ann Neurol 1992; 32: 123–130.

    Article  PubMed  Google Scholar 

  63. van Diemen HAM, Polman CH, Koetsier JC, van Loenen AC, Nauta JJP, Bertelsmann FW. 4-Aminopyridine in patients with multiple sclerosis: dosage and serum level related to efficacy and safety. Clin Neuropharm 1993; 16: 195–204.

    Article  Google Scholar 

  64. Ellison GW, Myers LW, Mickey MR, Graves MC, Tourtellotte WW, Syndulko K, et al. A placebo-controlled, randomized, double-blind, variable-dosage, clinical trial of azathioprine with and without methylprednisolone in multiple sclerosis. Neurology 1989; 39: 1018–1026.

    Article  PubMed  CAS  Google Scholar 

  65. Nuwer MR, Packwood JW, Myers LW, Ellison GW. Evoked potentials predict the clinical changes in multiple sclerosis drug study. Neurology 1987; 37: 1754–1761.

    Article  PubMed  CAS  Google Scholar 

  66. Vickrey BG, Hays RD, Harooni R, Myers LW, Ellison GW. A health-related quality of life measure for multiple sclerosis. Qual Life Res 1995; 4: 187–206.

    Article  PubMed  CAS  Google Scholar 

  67. LaRocca NG, Ritvo PG, Miller DM, Fischer JS, Andrews H, Paty D. Quality of life assessment in multiple sclerosis trials: current status and strategies for improving multiple sclerosis clinical trial design. In: Goodkin DE, Rudick RA, editors. Multiple sclerosis: advances in clinical trial design, treatment and future perspectives. Berlin Heidelberg New York: Springer, 1996: 145–160.

    Google Scholar 

  68. Devins GM, Seland TP. Emotional impact of multiple sclerosis: recent findings and suggestions for future research. psychol Bull 1987; 101: 363–375.

    CAS  Google Scholar 

  69. Aronson KJ. Quality of life among persons with multiple sclerosis and their caregivers. Neurology 1997; 48: 74–80.

    Article  PubMed  CAS  Google Scholar 

  70. Rudick RA, Miller D, Clough JD, Gragg LA, Farmer RG. Quality of life in multiple sclerosis: comparison with inflammatory bowel disease and rheumatoid arthritis. Arch Neurol 1992; 49: 1237–1242.

    Article  PubMed  CAS  Google Scholar 

  71. Petajan JH, Gappmaier E, White AT, Spencer MK, et al. Impact of aerobic training on fitness and quality of life in multiple sclerosis. Ann Neurol 1996; 39: 432–441.

    Article  PubMed  CAS  Google Scholar 

  72. Cookfair DL, Fischer J, Rudick R, Bourdette D, O’Reilly K, Jacobs L, et al. Quality of life in low-disability multiple sclerosis patients participating in a phase III trial of interferon beta-la for relapsing multiple sclerosis. Ann Neurol 1996; 40: 550.

    Google Scholar 

  73. Rudick RA, Goodkin DE, Jacobs LD, Cookfair DL, Herndon RM, Richert JR, et al. Impact of interferon beta-la on neurologic disability in relapsing multiple sclerosis. Neurology 1997; 49: 358–363.

    Article  PubMed  CAS  Google Scholar 

  74. Bergner M, Bobbitt RA, Pollard WE, Martin DP, Gilson DS. The sickness impact profile: validation of a health status measure. Med Care 1976; 14: 57–67.

    Article  PubMed  CAS  Google Scholar 

  75. Bergner M, Bobbitt RA, Carter B, Gilson BS. The Sickness Impact Profile: development and final revision of a health status measure. Med Care 1981; 19: 787–805.

    Article  PubMed  CAS  Google Scholar 

  76. Ware JE, Sherbourne CD. The MOS 36-item Short Form Health Survey (SF-36). Med Care 1992; 30: 473–481.

    Article  PubMed  Google Scholar 

  77. Ware JE, Snow KK, Kosinski M, Gandek B. SF-36 Health Survey: manual and interpretation guide. Boston, MA: The Health Institute, New England Medical Center, 1993.

    Google Scholar 

  78. Fleming TR, Harrington DP, O’Brien PC. Designs for group sequential test. Control Clin Trials 1984; 5: 348–361.

    Article  PubMed  CAS  Google Scholar 

  79. Anderson S, Auquier A, Hauck WW. Statistical methods for comparative studies: techniques for bias reduction. New York: Wiley, 1980.

    Book  Google Scholar 

  80. Kaplan EL, Meier P. Nonparametric estimation from incomplete observations. J Am Stat Assoc 1958; 53: 457–481.

    Article  Google Scholar 

  81. Kalbfleish JD, Prentice RL. The statistical analysis of failure time data. New York: Wiley, 1980.

    Google Scholar 

  82. Mantel N. Evaluation of survival data and two new rank order statistics arising in its consideration. Cancer Chemoth Reports 1966; 50: 163–170.

    CAS  Google Scholar 

  83. Peto R, Pike MC, Armitage P, Breslow NE, Cox DR, Howard SV, et al. Design and analysis of randomized clinical trials requiring prolonged observation of each patient. Br J Cancer 1977; 35: 1–39.

    Article  PubMed  CAS  Google Scholar 

  84. Bornstein MB, Miller A, Slagle S, Weitzman M, Drexler E, Keilson M, et al. A placebo-controlled, double-blind, randomized, two-center, pilot trial of Cop 1 in chronic progressive multiple sclerosis. Neurology 1991; 41: 533–539.

    Article  PubMed  CAS  Google Scholar 

  85. Rudick RA, Cookfair DL. Conduct of clinical trials in multiple sclerosis. In: Raine CS, McFarland HF, Tourtellotte WW, editors. Multiple sclerosis: clinical and pathogenetic basis. London: Chapman and Hall, 1997: 341–353.

    Google Scholar 

  86. Cox DR. Regression models and life tables. J R Stat Soc 1972; 34: 187–220.

    Google Scholar 

  87. Fleiss JL. The design and analysis of clinical experiments. New York: Wiley, 1986.

    Google Scholar 

  88. Bornstein MB, Miller A, Slagle S, Weitzman M, Crystal H, Drexler E, et al. A pilot trial of Cop 1 in exacerbating-remitting multiple sclerosis. N Engl J Med 1987; 317: 408–414.

    Google Scholar 

Download references

Authors
  1. D. L. Cookfair
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. B. Weinstock-Guttman
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. J. A. Cohen
    View author publications

    You can also search for this author in PubMed Google Scholar

Editor information

Editors and Affiliations

  1. Neuromuscular Unit, West London Neurosciences Centre, 1st Floor Pilot Wing, Charing Cross Hospital, Fulham Palace Road, W6 8RF, London, UK

    Roberto J. Guiloff MD, FRCP (Consultant Neurologist) (Consultant Neurologist)

Rights and permissions

Reprints and permissions

Copyright information

© 2001 Springer-Verlag London

About this chapter

Cite this chapter

Cookfair, D.L., Weinstock-Guttman, B., Cohen, J.A. (2001). Multiple Sclerosis: Experience with Large Clinical Trials. In: Guiloff, R.J. (eds) Clinical Trials in Neurology. Springer, London. https://doi.org/10.1007/978-1-4471-3787-0_32

Download citation

  • DOI: https://doi.org/10.1007/978-1-4471-3787-0_32

  • Publisher Name: Springer, London

  • Print ISBN: 978-1-84996-856-0

  • Online ISBN: 978-1-4471-3787-0

  • eBook Packages: Springer Book Archive

Publish with us

Policies and ethics

Search

Navigation